The frequency is high, and probably underestimated
The reference figures used by the US prevention agency cover the period 2007 to 2010: in adults aged 30 to 70, the prevalence of at least mild apnea, an apnea-hypopnea index of 5 or more, combined with daytime sleepiness, was 14 percent in men and 5 percent in women. For a moderate to severe form, index of 15 or more, it was 13 percent in men and 6 percent in women.
A more recent estimate, adjusted for obesity as a major risk factor, projects 83.7 million affected adults in the United States in 2024, a global prevalence of 32.4 percent, with 59 percent men and 41 percent women. The gap with earlier figures owes as much to the definition used and the rise in obesity as to a change in method.
The consequences of an untreated severe form are documented: increased all cause mortality, cardiovascular disease and cerebrovascular events, type 2 diabetes, cognitive impairment, degraded quality of life, and road accidents. So this is not a comfort problem, and that is what makes what follows counterintuitive.
Despite this, screening the general population is not recommended
In 2022, the US prevention agency updated its 2017 position after a systematic review of the benefits and harms of screening. Its conclusion is that the available evidence is insufficient to assess the balance of benefits and harms of screening for obstructive sleep apnea in the general adult population.
The population this conclusion targets is precise: asymptomatic adults, and adults with unrecognized symptoms. In other words, a person who complains does not fall under this recommendation, they fall under an ordinary diagnostic pathway. The absence of a screening recommendation is not an invitation to inaction.
For a practitioner, that nuance is decisive. Giving everyone a questionnaire rests on nothing solid, and mainly produces false positives, worry and unnecessary tests. Spotting a person who shows signs and referring them, by contrast, rests on accepted clinical logic.
Symptoms do not present the same way according to sex
The Cochrane review devoted to myofunctional therapy describes this difference explicitly. The classic symptoms, snoring, non restorative rest and daytime sleepiness, are reported mainly by men.
Women report more non specific symptoms: lack of energy, fatigue, sleep onset insomnia and morning headaches. That gap explains part of the diagnostic delay in women, and it also explains why questionnaires built on classic symptoms catch them poorly.
For a practitioner receiving a woman complaining of persistent fatigue and waking with a headache, the useful reflex is not to conclude, it is to ask about nighttime sleep, snoring reported by those around her and observed breathing pauses, then to refer. Chronic fatigue is one of the reasons practitioners most often miss.
Wearables detect something, but they diagnose nothing
A 2024 systematic review with meta-analysis assessed the ability of wearable devices integrating artificial intelligence algorithms to identify sleep apnea, distinguish its type and estimate its severity, with risk of bias assessed by a tool suited to diagnostic accuracy studies.
The argument made for these tools is their convenience, their accessibility, their cost and the possibility of continuous tracking, against the limits of polysomnography. The argument is real, and that is why these devices arrive in consultation, often with several months of history.
What a practitioner should do with it is limited, however. A repeated signal of desaturation or respiratory events reported by a watch is a reason to refer, not a diagnosis, and even less a severity measure on which to base coaching. Saying so clearly avoids the opposite situation, where a person reassured by their app never consults.
Treatments are changing, and that changes what you say
Continuous positive airway pressure remains the first line treatment for most affected people, but adherence is often insufficient, which the literature acknowledges explicitly. A 2025 meta-analysis combining randomized trials and non randomized studies adjusted for confounders revisited the question of its effect on mortality, precisely because earlier data were contradictory.
On the drug side, the SURMOUNT-OSA trial published in 2024 tested tirzepatide in people with moderate to severe apnea and obesity. Baseline apnea-hypopnea index averaged 51.5 and 49.5 events per hour depending on the trial, for a mean body mass index of 39.1 and 38.7.
At 52 weeks, the mean change was 25.3 fewer events per hour on tirzepatide against 5.3 fewer on placebo in the first trial, and 29.3 against 5.5 in the second, a treatment difference of about 20 to 24 events per hour. The most frequent adverse events were digestive, most often mild to moderate. A practitioner does not have to take a position on these treatments, but must know that a person may arrive with that option in mind.
The practitioner's role, and its exact limit
Collecting signs, asking those around about breathing pauses and snoring, spotting daytime sleepiness that interferes with driving, and measuring neck and waist circumference as part of a usual assessment fall to the practitioner. So do the underlying levers, physical activity and weight management, which act on a major risk factor.
Making a diagnosis, interpreting an apnea-hypopnea index, deciding on a sleep recording and any judgment of severity do not. These acts require an examination prescribed and interpreted by a physician, and a person with sleepiness at the wheel must be referred without delay.
Finally, one has to accept not explaining everything by apnea. Persistent fatigue may come from a disorganized sleep-wake rhythm, a sleep onset disorder or a chronic sleep debt, and these mechanisms call for a chronobiological reading of sleep before any respiratory hypothesis. The rule stays the same: spot, explain, refer.
Sources
- 1.US Preventive Services Task Force. Screening for Obstructive Sleep Apnea in Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2022.
- 2.Sonmez I, et al. Unmasking obstructive sleep apnea: Estimated prevalence and impact in the United States. Respir Med. 2025.
- 3.Benjafield AV, et al. Positive airway pressure therapy and all-cause and cardiovascular mortality in people with obstructive sleep apnoea: a systematic review and meta-analysis. Lancet Respir Med. 2025.
- 4.Malhotra A, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024.
- 5.Abd-Alrazaq A, et al. Detection of Sleep Apnea Using Wearable AI: Systematic Review and Meta-Analysis. J Med Internet Res. 2024.
- 6.Rueda JR, et al. Myofunctional therapy (oropharyngeal exercises) for obstructive sleep apnoea. Cochrane Database Syst Rev. 2020.
- 7.Kanu C, et al. Effect of tirzepatide treatment on patient-reported outcomes among SURMOUNT-OSA participants. Sleep. 2025.
- 8.Abelleira R, et al. Diabetes and obstructive sleep apnoea: A case-control study. Med Clin (Barc). 2024.
- 9.Bradley TD, et al. Adaptive servo-ventilation for sleep-disordered breathing in patients with heart failure with reduced ejection fraction. Lancet Respir Med. 2024.
Reading studies is one thing, turning them into a plan is another
The Longevity Practitioner certification teaches the method that turns this kind of data into an accompaniment decision: assess, prioritise, plan over 90 days, re-measure, and know when to hand over.
11 modules, €2,200. Enrol
Continue reading
Benjamin Sant
Co-founder of the School of Longevity
Cofounder of the School of Longevity with Tristan Maruyama. A former officer trained at Saint-Cyr from 2019 to 2022 and a coach since 2018, he has supported more than 4,000 people. He leads the School's editorial content with one constant principle: pass on only what can be situated, verified and applied seriously.
This article is published for information and education. It does not replace medical advice. For any personal health question, consult a healthcare professional.
